Jacklynn V. Egger

SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization

Marina K. Baine, Min‐Shu Hsieh, W. Victoria Lai et al. · Journal of Thoracic Oncology · 2020 · 501 citations · Full text

Medicine, Cancer Biology, Molecular Biology +8

Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer

Joseph M. Chan, Àlvaro Quintanal-Villalonga, Vianne R. Gao et al. · Cancer Cell · 2021 · 430 citations · Full text

Medicine, Cancer Biology, Oncology +17

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

Biagio Ricciuti, Kathryn C. Arbour, Amir Vajdi et al. · Journal of Thoracic Oncology · 2021 · 367 citations · Full text

Medicine, Molecular Biology, Oncology +17

Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer

R. Vanguri, Jia Luo, Andrew Aukerman et al. · Nature Cancer · 2022 · 361 citations · Full text

Medicine, Oncology, Radiology +17

Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas

A.J. Schoenfeld, H. Rizvi, Chai Bandlamudi et al. · Annals of Oncology · 2020 · 341 citations · Full text

Medicine, Oncology, Pathology +16